Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the two thousand seventeen American Society of Clinical Oncology Annual Meeting (NASDAQ: KITE)
Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the two thousand seventeen American Society of Clinical Oncology Annual Meeting
- Clinical and Biomarker Correlates of Outcomes in ZUMA-1 Pivotal Trial of axicabtagene ciloleucel in Refractory, Aggressive Non-Hodgkin Lymphoma (NHL)
- Updated Efficacy and Safety Data from ZUMA-3, a Phase 1/Two explore of KTE-C19 in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Health Economics and Outcomes Research Abstract on Current Treatment Cost for Diffuse Large B-Cell Lymphoma (DLBCL)
SANTA MONICA, Calif. –(BUSINESS WIRE)– Kite Pharma, Inc. (Nasdaq:KITE) today announced fresh data presentations from numerous studies related to its lead investigational candidate, axicabtagene ciloleucel (also known as KTE-C19), at the two thousand seventeen American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL , June 2-6, two thousand seventeen . The total text for abstracts is available online through the ASCO website at http://abstracts.asco.org.
“The presentations at ASCO proceed to enhance our growing skill on the potential for cell therapy,” said
, M.D., Ph.D., Executive Vice President of Research and Development and Chief Medical Officer of Kite. “The translational insights from these data presentations are invaluable as we advance axicabtagene ciloleucel/KTE-C19 and seek to optimize treatment, not only in NHL, but also across a broad range of hematologic malignancies.”
Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)
- Abstract #7512
- Session: Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Poster Board #274
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Poster Discussion Session Time/Location: Monday, June Five, two thousand seventeen : 1:15-2:30 PM CDT , E354b
- Presenter:
Frederick L. Locke
, M.D., Moffitt Cancer Center , Tampa, FL
Updated results from ZUMA-3, a phase 1/Two examine of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)
- Abstract #3024
- Session: Poster Session: Developmental Therapeutics – Immunotherapy
- Poster Board #119
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
, M.D., Moffitt Cancer Center , Tampa, FL
Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)
- Abstract #3023
- Session: Poster Session: Developmental Therapeutics – Immunotherapy
- Poster Board #118
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
Frederick L. Locke
, M.D., Moffitt Cancer Center , Tampa, FL
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)
- Abstract #3025
- Session: Poster Session: Developmental Therapeutics – Immunotherapy
- Poster Board #120
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
, Ph.D., Laboratory of Integrative Cancer Immunology , INSERM
ZUMA-6: Phase 1-2 multicenter probe evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL)
- Abstract #TPS7572
- Session: Trials in Progress Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Poster Board #331a
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
Frederick L. Locke
, M.D., Moffitt Cancer Center , Tampa, FL
Total 1-year cost of diffuse large B-cell lymphoma (DLBCL) beyond first-line (1L) therapy: A retrospective cohort analysis
About axicabtagene ciloleucel
Kite’s lead product candidate, axicabtagene ciloleucel, previously known as KTE-C19, is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein voiced on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a objective of providing rapid, long-term durable response and eliminating the cargo of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system’s capability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to go after @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the capability to advance axicabtagene ciloleucel/KTE-C19 and optimize treatment in NHL and across a broad range of hematologic malignancies. Various factors may cause differences inbetween Kite’s expectations and actual results as discussed in greater detail in Kite’s filings with the Securities and Exchange Commission , including without limitation in its Form 10-Q for the quarter ended March 31, two thousand seventeen . Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of fresh information, future events or otherwise, after the date of this press release.
Kite Pharma, Inc.
SVP, Corporate Communications & Investor Relations
Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the two thousand seventeen American Society of Clinical Oncology Annual Meeting (NASDAQ: KITE)
Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the two thousand seventeen American Society of Clinical Oncology Annual Meeting
- Clinical and Biomarker Correlates of Outcomes in ZUMA-1 Pivotal Trial of axicabtagene ciloleucel in Refractory, Aggressive Non-Hodgkin Lymphoma (NHL)
- Updated Efficacy and Safety Data from ZUMA-3, a Phase 1/Two examine of KTE-C19 in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Health Economics and Outcomes Research Abstract on Current Treatment Cost for Diffuse Large B-Cell Lymphoma (DLBCL)
SANTA MONICA, Calif. –(BUSINESS WIRE)– Kite Pharma, Inc. (Nasdaq:KITE) today announced fresh data presentations from numerous studies related to its lead investigational candidate, axicabtagene ciloleucel (also known as KTE-C19), at the two thousand seventeen American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL , June 2-6, two thousand seventeen . The total text for abstracts is available online through the ASCO website at http://abstracts.asco.org.
“The presentations at ASCO proceed to enhance our growing skill on the potential for cell therapy,” said
, M.D., Ph.D., Executive Vice President of Research and Development and Chief Medical Officer of Kite. “The translational insights from these data presentations are invaluable as we advance axicabtagene ciloleucel/KTE-C19 and seek to optimize treatment, not only in NHL, but also across a broad range of hematologic malignancies.”
Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)
- Abstract #7512
- Session: Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Poster Board #274
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Poster Discussion Session Time/Location: Monday, June Five, two thousand seventeen : 1:15-2:30 PM CDT , E354b
- Presenter:
Frederick L. Locke
, M.D., Moffitt Cancer Center , Tampa, FL
Updated results from ZUMA-3, a phase 1/Two investigate of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)
- Abstract #3024
- Session: Poster Session: Developmental Therapeutics – Immunotherapy
- Poster Board #119
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
, M.D., Moffitt Cancer Center , Tampa, FL
Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)
- Abstract #3023
- Session: Poster Session: Developmental Therapeutics – Immunotherapy
- Poster Board #118
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
Frederick L. Locke
, M.D., Moffitt Cancer Center , Tampa, FL
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)
- Abstract #3025
- Session: Poster Session: Developmental Therapeutics – Immunotherapy
- Poster Board #120
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
, Ph.D., Laboratory of Integrative Cancer Immunology , INSERM
ZUMA-6: Phase 1-2 multicenter probe evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL)
- Abstract #TPS7572
- Session: Trials in Progress Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Poster Board #331a
- Session Time/Location: Monday, June Five, two thousand seventeen : 8:00-11:30 AM CDT , Hall A
- Presenter:
Frederick L. Locke
, M.D., Moffitt Cancer Center , Tampa, FL
Total 1-year cost of diffuse large B-cell lymphoma (DLBCL) beyond first-line (1L) therapy: A retrospective cohort analysis
About axicabtagene ciloleucel
Kite’s lead product candidate, axicabtagene ciloleucel, previously known as KTE-C19, is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein voiced on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a purpose of providing rapid, long-term durable response and eliminating the cargo of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system’s capability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to go after @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the capability to advance axicabtagene ciloleucel/KTE-C19 and optimize treatment in NHL and across a broad range of hematologic malignancies. Various factors may cause differences inbetween Kite’s expectations and actual results as discussed in greater detail in Kite’s filings with the Securities and Exchange Commission , including without limitation in its Form 10-Q for the quarter ended March 31, two thousand seventeen . Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of fresh information, future events or otherwise, after the date of this press release.
Kite Pharma, Inc.
SVP, Corporate Communications & Investor Relations
